“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
|Articles|June 1, 1999
Oncology NEWS International
- Oncology NEWS International Vol 8 No 6
- Volume 8
- Issue 6
Tobacco Billboard Advertising Falls by the Roadside
WASHINGTON-“No Bull,” no more. Decades of tobacco advertising on outdoor billboards have come to an end. On April 22, under the agreement reached last year between the tobacco industry and 46 states, four large tobacco companies removed tobacco advertising from more than 3,000 billboards nationwide.
Advertisement
WASHINGTONNo Bull, no more. Decades of tobacco advertising on outdoor billboards have come to an end. On April 22, under the agreement reached last year between the tobacco industry and 46 states, four large tobacco companies removed tobacco advertising from more than 3,000 billboards nationwide.
In many instances, the tobacco promotionals were replaced by anti-tobacco ads, which will remain until the companies leases on the billboards expire, most of them in January 2000.
Articles in this issue
over 27 years ago
Opioids Are Often Ignored for Treating Neuropathic Painover 27 years ago
Study Suggests Short Time Interval for Ovarian Cancer Screeningover 27 years ago
Your Strengths, Market’s Demands Dictate Marketing Strategiesover 27 years ago
First-Line Irinotecan Effective in Advanced Colorectal Cancerover 27 years ago
Doctor Ponders Popularity of Alternative Medicineover 27 years ago
Can Physicians Be Held Liable for Alternative Medicine?over 27 years ago
Tips on Marketing Your Oncology Practice to Patientsover 27 years ago
Biologics Research Promises ‘Synergistic’ Cancer Therapyover 27 years ago
Patient Care Costs of Clinical Trials May Be Less Than Standard Careover 27 years ago
Sentinal Node Biopsy Finds 98% of Metastic Colon CancersAdvertisement
Related to this article
KEYNOTE-B49 data show pembrolizumab plus chemotherapy improved PFS but not OS in PD-L1–positive HR+/HER2– advanced breast cancer.
Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.
ASTRO now recommends moderate hypofractionation for all risk groups and SBRT as a standard option in low- and intermediate-risk localized prostate cancer.
Futibatinib, pemigatinib, and lirafugratinib showed similar response rates and progression-free survival at first FGFR inhibitor exposure in biliary tract cancers with FGFR alterations.
Frontline iza-bren plus pembrolizumab yielded a 57.9% ORR in recurrent or metastatic HNSCC at 2.5 mg/kg, the dose chosen for phase 3 study.
In the real-world CEMI-LUNG study, first-line cemiplimab produced survival and response outcomes consistent with the pivotal EMPOWER-Lung 1 trial.
Data from the phase 3 OptiTROP-Lung06 trial may support sacituzumab tirumotecan plus pembrolizumab as a new frontline option for this NSCLC population.
Advertisement
Advertisement
Trending on CancerNetwork
1
Cardiac Assessment With Atrial Fibrillation and Closing Thoughts
2
Cisplatin-Free Pembrolizumab Regimen Misses Primary End Point in SMART-KEY
3
Encorafenib/Binimetinib Plus Pembrolizumab Extends PFS in BRAF V600 Melanoma
4
Real-World Data on Cemiplimab Monotherapy Align With Prior NSCLC Studies
5